Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 25, 2007

Date of Report (Date of earliest event reported)

NPS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-23272   87-0439579

(State or other jurisdiction of

incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification Number)

550 Hills Drive Drive

Bedminster, NJ 07921

(Address of principal executive offices)

(908) 450-5300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01. Other Events.

NPS Pharmaceuticals, Inc. announced today that it will report its third quarter financial results and Nycomed’s decision whether to proceed with ex-U.S. development and commercialization of GATTEX™ (teduglutide) on Thursday, November 1, 2007. The announcement will be followed by a conference call and webcast at 5:00 p.m. Details about the conference call on the third quarter results are provided in the press release attached hereto as Exhibit 99.1

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   

Description

99.1    Press Release issued by NPS Pharmaceuticals dated October 25, 2007 relating to release of its third quarter financial results and conference call.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 25, 2007     NPS PHARMACEUTICALS, INC.
      By:   /s/ VAL R. ANTCZAK
        Val R. Antczak, Senior Vice President, Legal Affairs, General Counsel and Secretary